TENX
Income statement / Annual
Last year (2024), Tenax Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Tenax Therapeutics, Inc.'s net income was -$17.60 M.
See Tenax Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
04/30/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$49.29 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$113.33 K
|
$108.98 K
|
$114.75 K
|
$107.28 K
|
$9.02 K
|
$13.62 K
|
$18.95 K
|
$9.73 K
|
| Gross Profit |
$0.00
|
-$7.57 K
|
-$113.33 K
|
-$108.98 K
|
-$114.75 K
|
-$107.28 K
|
-$9.02 K
|
-$13.62 K
|
-$18.95 K
|
$39.56 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.8
|
| Research and Development Expenses |
$12.71 M
|
$3.23 M
|
$5.38 M
|
$25.15 M
|
$4.56 M
|
$3.47 M
|
$1.24 M
|
$3.53 M
|
$35.14 M
|
$6.66 M
|
| General & Administrative Expenses |
$6.79 M
|
$5.01 M
|
$5.68 M
|
$7.58 M
|
$5.31 M
|
$5.08 M
|
$5.65 M
|
$5.68 M
|
$6.25 M
|
$7.17 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.79 M
|
$5.01 M
|
$5.68 M
|
$7.58 M
|
$5.31 M
|
$5.08 M
|
$5.65 M
|
$5.68 M
|
$6.25 M
|
$7.17 M
|
| Other Expenses |
$0.00
|
-$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$33.27 M
|
-$9.68 M
|
| Operating Expenses |
$19.49 M
|
$8.23 M
|
$11.05 M
|
$32.73 M
|
$9.87 M
|
$8.56 M
|
$6.89 M
|
$9.21 M
|
$52.65 M
|
$13.83 M
|
| Cost And Expenses |
-$19.49 M
|
$8.23 M
|
$11.05 M
|
$32.73 M
|
$9.87 M
|
$8.56 M
|
$6.89 M
|
$9.21 M
|
$52.65 M
|
$15.69 M
|
| Interest Income |
$1.91 M
|
$0.00
|
$4.44
|
$0.95
|
$31.00 K
|
$144.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$23.00 K
|
$23.97 K
|
$4.44 K
|
$949.00
|
$1.63 K
|
$0.00
|
$0.00
|
$0.00
|
$32.50 M
|
$49.08 K
|
| Depreciation & Amortization |
$46.00 K
|
$7.57 K
|
$113.33 K
|
$108.98 K
|
$114.75 K
|
$107.28 K
|
$9.02 K
|
$13.62 K
|
$18.95 K
|
$46.84 K
|
| EBITDA |
-$17.58 M |
-$8.23 M |
-$10.93 M |
-$32.36 M |
-$9.74 M |
-$8.55 M |
-$6.88 M |
-$9.19 M |
-$51.87 M |
-$15.59 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-316.35
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-317.3
|
| Total Other Income/Expenses Net |
$1.89 M
|
$523.27 K
|
$4.75 K
|
$253.88 K
|
$16.54 K
|
$160.90 K
|
$79.84 K
|
$366.22 K
|
$764.74 K
|
$536.30 K
|
| Income Before Tax |
-$17.60 M
|
-$7.71 M
|
-$11.05 M
|
-$32.47 M
|
-$9.85 M
|
-$8.39 M
|
-$6.81 M
|
-$8.84 M
|
-$51.89 M
|
-$15.10 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-306.41
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$7.96 M
|
$0.00
|
| Net Income |
-$17.60 M
|
-$7.71 M
|
-$11.05 M
|
-$32.47 M
|
-$9.85 M
|
-$8.39 M
|
-$6.81 M
|
-$8.84 M
|
-$43.92 M
|
-$14.08 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-285.72
|
| EPS |
-1.15 |
-31.09 |
-600.8 |
-2524.8 |
-1523.8 |
-26.6 |
-7359.14 |
-10022.32 |
-624.82 |
-200.61 |
| EPS Diluted |
-1.15 |
-31.04 |
-600.8 |
-2524.8 |
-1523.8 |
-26.6 |
-7359.14 |
-10022.32 |
-624.82 |
-200.61 |
| Weighted Average Shares Out |
$15.27 M
|
$248.00 K
|
$18.39 K
|
$12.86 K
|
$4.64 K
|
$3.87 K
|
$915.00
|
$1.41 M
|
$878.74
|
$70.19 K
|
| Weighted Average Shares Out Diluted |
$15.27 M
|
$248.45 K
|
$18.39 K
|
$12.86 K
|
$4.64 K
|
$3.87 K
|
$915.00
|
$1.41 M
|
$878.74
|
$70.19 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
